Comparison Overview

MACLEODS PHARMACEUTICALS LTD.

VS

AUROBINDO PHARMA LTD

MACLEODS PHARMACEUTICALS LTD.

304, Atlanta Arcade Marol Church Road, Andheri East, Mumbai, Maharashtra, IN, 400059
Last Update: 2025-12-10
View Profile
Between 750 and 799
https://www.macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 11,522
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

AUROBINDO PHARMA LTD

Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District,, Hyderabad, Telangana, IN, 500032
Last Update: 2025-12-09
Between 750 and 799
https://www.aurobindo.com/

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 14,616
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/macleods-pharmaceuticals-ltd..jpeg
MACLEODS PHARMACEUTICALS LTD.
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/aurobindopharma.jpeg
AUROBINDO PHARMA LTD
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
MACLEODS PHARMACEUTICALS LTD.
100%
Compliance Rate
0/4 Standards Verified
AUROBINDO PHARMA LTD
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for MACLEODS PHARMACEUTICALS LTD. in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for AUROBINDO PHARMA LTD in 2025.

Incident History — MACLEODS PHARMACEUTICALS LTD. (X = Date, Y = Severity)

MACLEODS PHARMACEUTICALS LTD. cyber incidents detection timeline including parent company and subsidiaries

Incident History — AUROBINDO PHARMA LTD (X = Date, Y = Severity)

AUROBINDO PHARMA LTD cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/macleods-pharmaceuticals-ltd..jpeg
MACLEODS PHARMACEUTICALS LTD.
Incidents

No Incident

https://images.rankiteo.com/companyimages/aurobindopharma.jpeg
AUROBINDO PHARMA LTD
Incidents

No Incident

FAQ

AUROBINDO PHARMA LTD company demonstrates a stronger AI Cybersecurity Score compared to MACLEODS PHARMACEUTICALS LTD. company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, AUROBINDO PHARMA LTD company has disclosed a higher number of cyber incidents compared to MACLEODS PHARMACEUTICALS LTD. company.

In the current year, AUROBINDO PHARMA LTD company and MACLEODS PHARMACEUTICALS LTD. company have not reported any cyber incidents.

Neither AUROBINDO PHARMA LTD company nor MACLEODS PHARMACEUTICALS LTD. company has reported experiencing a ransomware attack publicly.

Neither AUROBINDO PHARMA LTD company nor MACLEODS PHARMACEUTICALS LTD. company has reported experiencing a data breach publicly.

Neither AUROBINDO PHARMA LTD company nor MACLEODS PHARMACEUTICALS LTD. company has reported experiencing targeted cyberattacks publicly.

Neither MACLEODS PHARMACEUTICALS LTD. company nor AUROBINDO PHARMA LTD company has reported experiencing or disclosing vulnerabilities publicly.

Neither MACLEODS PHARMACEUTICALS LTD. nor AUROBINDO PHARMA LTD holds any compliance certifications.

Neither company holds any compliance certifications.

Neither MACLEODS PHARMACEUTICALS LTD. company nor AUROBINDO PHARMA LTD company has publicly disclosed detailed information about the number of their subsidiaries.

AUROBINDO PHARMA LTD company employs more people globally than MACLEODS PHARMACEUTICALS LTD. company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither MACLEODS PHARMACEUTICALS LTD. nor AUROBINDO PHARMA LTD holds SOC 2 Type 1 certification.

Neither MACLEODS PHARMACEUTICALS LTD. nor AUROBINDO PHARMA LTD holds SOC 2 Type 2 certification.

Neither MACLEODS PHARMACEUTICALS LTD. nor AUROBINDO PHARMA LTD holds ISO 27001 certification.

Neither MACLEODS PHARMACEUTICALS LTD. nor AUROBINDO PHARMA LTD holds PCI DSS certification.

Neither MACLEODS PHARMACEUTICALS LTD. nor AUROBINDO PHARMA LTD holds HIPAA certification.

Neither MACLEODS PHARMACEUTICALS LTD. nor AUROBINDO PHARMA LTD holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

NXLog Agent before 6.11 can load a file specified by the OPENSSL_CONF environment variable.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 8.1
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:H/I:H/A:H
References
Description

uriparser through 0.9.9 allows unbounded recursion and stack consumption, as demonstrated by ParseMustBeSegmentNzNc with large input containing many commas.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 2.9
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L
References
Description

A vulnerability was detected in Mayan EDMS up to 4.10.1. The affected element is an unknown function of the file /authentication/. The manipulation results in cross site scripting. The attack may be performed from remote. The exploit is now public and may be used. Upgrading to version 4.10.2 is sufficient to fix this issue. You should upgrade the affected component. The vendor confirms that this is "[f]ixed in version 4.10.2". Furthermore, that "[b]ackports for older versions in process and will be out as soon as their respective CI pipelines complete."

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss2
Base: 5.0
Severity: LOW
AV:N/AC:L/Au:N/C:N/I:P/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

MJML through 4.18.0 allows mj-include directory traversal to test file existence and (in the type="css" case) read files. NOTE: this issue exists because of an incomplete fix for CVE-2020-12827.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 4.5
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:L/I:N/A:L
References
Description

A half-blind Server Side Request Forgery (SSRF) vulnerability exists in kube-controller-manager when using the in-tree Portworx StorageClass. This vulnerability allows authorized users to leak arbitrary information from unprotected endpoints in the control plane’s host network (including link-local or loopback services).

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 5.8
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:H/UI:N/S:C/C:H/I:N/A:N
References